Varicella Zoster Vaccine (Recombinant)


Description

Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles. First approved in October 2017 by the Food and Drug Administration, Shingrix is t...

Read more

Pharmacology

Indication

Shingrix vaccine is indicated for the prevention of herpes zoster (shingles) in adults aged 50 years... Read more

Pharmacodynamic

Information currently not available.

Mechanism of action

Shingrix provides protection against Herpes Zoster reactivation by eliciting an immune response to V... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Varicella Zoster Vaccine (Recombinant)


References

  • 1 . Bharucha T, Ming D, Breuer J: A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug 3;13(8):1789-1797. doi: 10.1080/21645515.2017.1317410. Epub 2017 Apr 20. [PubMed: 28426274]
  • 2 . New phase 3 data on shingles vaccine Shingrix presented at CDC Advisory Meeting. [Link]
  • 3 . CDC - Clinical Overview of Shingles (Herpes Zoster) [Link]
  • 4 . CDC - What Everyone Should Know about Shingles Vaccine [Link]

Recent Questions